The subgroup analyses were performed including the macrophage markers, the subgroup variable, and their interaction in the Cox model.
However, when we analyzed the expression pattern of uPA system markers in the subgroup of STS patients who underwent radical tumor resection (R0) we observed a trend towards an association between mRNA expression and disease-associated survival.
However, this is not an effective marker for the subgroup as up to 50% of Shh subgroup medulloblastomas are not nodular/desmoplastic.
According to any of the distinct sets of methylation markers, the highly methylated subgroups showed inferior clinical outcomes.
Therefore, medulloblastoma subgrouping is by far the best factor in terms of prognostication identified to date, but there is now a need for identifying better prognostic markers within each of the subgroups.
In subsequent statistical analyses, staining index was categorised in quartiles considering the frequency distribution for each marker, the size of the subgroups and the number of events in each category.
However, only a fraction of hrHPV positive women will have or develop CIN2+, arguing for the use of additive disease markers to distinguish the subgroup of women having a high likelihood of high-grade disease in need of further gynecologic examination.
Finally, we investigated the relationship between the expression levels of these surface markers and urinary AER in the subgroups based on aspirin intake.
For this purpose, we calculated three additional PCA maps, using the three proposed marker sets, for the subgroup of the LC patients, as a representative example.
The evaluation of the biologic markers in the different subgroups defined according to clinico-pathological characteristics showed that MVD median value was significantly higher in patients with an ECOG performance status of 1 than of 0, in proximal tumours and, unexpectedly, in those with well-moderately rather than poorly differentiated lesions.
